Asim A. Hameedi, M.D.; Stay of Decision and Transmittal Order, 30784 [2023-10212]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
30784
Federal Register / Vol. 88, No. 92 / Friday, May 12, 2023 / Notices
organization and (2) the nature and
scope of its standards development
activities. The notifications were filed
for the purpose of invoking the Act’s
provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Pursuant to section 6(b) of the Act, the
name and principal place of business of
the standards development organization
is: World Wide Web Consortium, Inc.,
Wakefield, MA. W3C was formed as a
Delaware non-stock member
corporation, organized exclusively for
exempt purposes within the meaning of
section 501(c)(3) of the Internal Revenue
Code of 1986, as amended (or the
corresponding provision of any future
United States Internal Revenue Law).
The nature and scope of W3C’s
standards development activities are: In
furtherance of such purposes, W3C is
organized and will be operated
primarily to continue the work of the
unincorporated World Wide Web
Consortium, with the charitable purpose
of inclusively developing
interoperability standards for the
infrastructure of the World Wide Web
(‘‘Web’’), so that all people may safely
and productively use the Web to
participate in society and improve their
lives. W3C seeks to achieve its purpose
by creating open, consensus-based Web
standards and guidelines to ensure that
the Web remains open, accessible, and
interoperable for everyone around the
globe, through processes intended to
promote fairness, transparency, and
accountability, and enable progress and
greater responsiveness to change.
Without limiting the foregoing, W3C,
through its member-driven approach,
will work to (a) foster a consistent
architecture accommodating the rapid
pace of progress in Web standards for
websites, browsers, data-sharing
applications, and devices to experience
all that the Web has to offer; (b) provide
a neutral forum where organizations
around the world come together to
create the technologies to most fully
realize the potential of the Web; (c)
ensure that all foundational Web
technologies meet the needs of civil
society, in areas such as accessibility,
internationalization, security, and
privacy; (d) provide standards that
undergird the infrastructure for modern
businesses leveraging the Web in areas
such as entertainment, communications,
digital publishing, and financial
services; (e) promote advances of
important associated social and
economic value; and (f) promote the
emergence of current and future
transformative phenomena, such as
VerDate Sep<11>2014
19:11 May 11, 2023
Jkt 259001
social media, e-commerce, video on the
web, and video conferencing.
Drug Enforcement Administration
Suzanne Morris,
Deputy Director, Civil Enforcement
Operations, Antitrust Division.
Asim A. Hameedi, M.D.; Stay of
Decision and Transmittal Order
[FR Doc. 2023–10207 Filed 5–11–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—ODVA, Inc.
Notice is hereby given that, on March
20, 2023, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), ODVA, Inc.
(‘‘ODVA’’) has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Inexbot Technology Co.
Ltd., Nanjing, PEOPLE’S REPUBLIC OF
CHINA, has been added as a party to
this venture.
Also, Asyril SA, Fribourg,
SWITZERLAND; and Telsonic AG,
Bronschhofen, SWITZERLAND, have
withdrawn as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and ODVA
intends to file additional written
notifications disclosing all changes in
membership.
On June 21, 1995, ODVA filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on February 15, 1996 (61 FR 6039).
The last notification was filed with
the Department on January 5, 2023. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on January 25, 2023 (88 FR 4851).
Suzanne Morris,
Deputy Director, Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2023–10209 Filed 5–11–23; 8:45 am]
BILLING CODE P
PO 00000
Frm 00073
Fmt 4703
Sfmt 9990
DEPARTMENT OF JUSTICE
On April 4, 2023, the Agency issued
a Decision and Order revoking, effective
May 11, 2023, Certificate of Registration
No. BH6407919 issued to Asim A.
Hameedi, M.D.1 Asim A. Hameedi,
M.D., 88 FR 21,715 (April 11, 2023). By
letter dated May 1, 2023 (letter),
addressed to the Drug Enforcement
Administration Administrator, Dr.
Hameedi requested that the April 4,
2023 Order be vacated 2 because, among
other reasons, he was never served with
the underlying Order to Show Cause.
Letter, at 1. Given the content of the
letter and its attachments, I hereby stay
the revocation of Certificate of
Registration No. BH6407919 issued to
Asim A. Hameedi, M.D., pending
further proceedings. Asim A. Hameedi,
M.D., 88 FR 21,715 (April 11, 2023).
This matter is transmitted to the
Office of Administrative Law Judges to
conduct any and all appropriate
proceedings (for example, to determine
the sufficiency of notice and/or whether
good cause exists to justify any delay).
It is so ordered.
Signing Authority
This document of the Drug
Enforcement Administration was signed
on May 9, 2023, by Administrator Anne
Milgram. That document with the
original signature and date is
maintained by DEA. For administrative
purposes only, and in compliance with
requirements of the Office of the Federal
Register, the undersigned DEA Federal
Register Liaison Officer has been
authorized to sign and submit the
document in electronic format for
publication, as an official document of
DEA. This administrative process in no
way alters the legal effect of this
document upon publication in the
Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug
Enforcement Administration.
[FR Doc. 2023–10212 Filed 5–11–23; 8:45 am]
BILLING CODE 4410–09–P
1 The Order also denied any pending application
to renew or modify this registration and denied any
other pending application by Dr. Hameedi for
registration in New York.
2 Dr. Hameedi also seeks to ‘‘excuse his default’’
citing to 21 CFR 1301.43(c)(1) and (f)(3). Letter, at
1. The default procedures Dr. Hameedi references
did not become effective until December 14, 2022,
and do not apply to his Order to Show Cause. 87
FR 73,246 (Nov. 29, 2022).
E:\FR\FM\12MYN1.SGM
12MYN1
]]>Agencies
[Federal Register Volume 88, Number 92 (Friday, May 12, 2023)]
[Notices]
[Page 30784]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10212]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Asim A. Hameedi, M.D.; Stay of Decision and Transmittal Order
On April 4, 2023, the Agency issued a Decision and Order revoking,
effective May 11, 2023, Certificate of Registration No. BH6407919
issued to Asim A. Hameedi, M.D.\1\ Asim A. Hameedi, M.D., 88 FR 21,715
(April 11, 2023). By letter dated May 1, 2023 (letter), addressed to
the Drug Enforcement Administration Administrator, Dr. Hameedi
requested that the April 4, 2023 Order be vacated \2\ because, among
other reasons, he was never served with the underlying Order to Show
Cause. Letter, at 1. Given the content of the letter and its
attachments, I hereby stay the revocation of Certificate of
Registration No. BH6407919 issued to Asim A. Hameedi, M.D., pending
further proceedings. Asim A. Hameedi, M.D., 88 FR 21,715 (April 11,
2023).
---------------------------------------------------------------------------
\1\ The Order also denied any pending application to renew or
modify this registration and denied any other pending application by
Dr. Hameedi for registration in New York.
\2\ Dr. Hameedi also seeks to ``excuse his default'' citing to
21 CFR 1301.43(c)(1) and (f)(3). Letter, at 1. The default
procedures Dr. Hameedi references did not become effective until
December 14, 2022, and do not apply to his Order to Show Cause. 87
FR 73,246 (Nov. 29, 2022).
---------------------------------------------------------------------------
This matter is transmitted to the Office of Administrative Law
Judges to conduct any and all appropriate proceedings (for example, to
determine the sufficiency of notice and/or whether good cause exists to
justify any delay).
It is so ordered.
Signing Authority
This document of the Drug Enforcement Administration was signed on
May 9, 2023, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-10212 Filed 5-11-23; 8:45 am]
BILLING CODE 4410-09-P
